A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy

DC_ICI_PC_1

To evaluate the safety and effectiveness of immune cell therapy using autologous bone marrow-derived dendritic cells and immune checkpoint inhibitors in patients with metastatic pancreatic cancer who have failed at least one standard anticancer treatment.

2024-03-01

2024-12-31

2025-12-31

Not yet recruiting

Early phase I

10

Inclusion Criteria: * Patients histologically confirmed to have pancreatic cancer and diagnosed as recurrent or metastatic * Patients whose disease was confirmed to have progressed according to RECIST v1.1 after 1st or more standard anticancer treatments * Patients satisfying systemic performance status ECOG 0-2 * Patients who have not undergone surgery, radiation therapy, or immunotherapy within 4 weeks and have recovered from side effects (However, tissue collection procedures that do not affect the test subject's condition are permitted at the discretion of the researcher.) * Patients who voluntarily agreed in writing to participate in this clinical study Exclusion Criteria: * Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years * Patients who have previously received anti-tumor immunotherapy (anti-PD1, anti-PDL-1, or CTLA4 inhibitor, etc.) or participated in clinical studies related to immunotherapy or cell therapy * Patients with active autoimmune disease requiring systemic immunosuppressive treatment * Patients with a history of organ or hematopoietic stem cell transplantation * Patients with acute or chronic infection requiring systemic treatment * Other cases where the test manager determines that it is not suitable for clinical research

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'dentritic cell + immunechekpoint inhibitor', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 10, 'type': 'ESTIMATED'}}

2023-12-15